Regencor is a privately held regenerative medicine company targeting heart disease, the #1 cause of death in the United States. We have discovered and patented that the hypoglycosylated variant of a normal circulating human protein, Follistatin-like 1, (FSTL1) drives heart muscle cells within the infarct zone to undergo controlled proliferation, thereby restoring ventricular contractility, reducing scar volume and preventing progression to heart failure. We are developing two sustained release microsphere formulations of our API, recombinant non-glycosylated human FSTL1 - MyoBeads for delivery to acute MI patients via the infarct related artery at the time of percutaneous coronary revascularization, and Q-Beads, a subcutaneous microsphere formulation of FSTL1 for administration to patients with heart failure. Our core mission is to reduce morbidity and mortality from myocardial infarction, and to prevent the progression to heart failure following MI.

Biotechnology

Regencor Inc.

Regencor Inc.'s headquarters in San Carlos, CA, United States

People (2)

Jobs (0)

Other offices